Zafrens

Zafrens

Biotechnology Research

San Diego, California 2,185 followers

Opening doors to new insights at the interface of biology, chemistry and engineering

About us

Zafrens is a therapeutics company pioneering an ultra-high throughput platform to isolate, culture, image, and sequence millions of cells per day. The proprietary platform allows for full characterization of diverse cell populations, as well as directly correlating molecular profiles (DNA, RNA, protein) to cell phenotype and function. The company’s mission is to unlock the full story of every cell to accelerate drug discovery.

Website
http://www.zafrens.com
Industry
Biotechnology Research
Company size
11-50 employees
Headquarters
San Diego, California
Type
Privately Held
Founded
2022

Locations

Employees at Zafrens

Updates

  • Zafrens reposted this

    "We think [this approach] to drug discovery and analysis where we miniaturize everything - we do high throughput experiments, but also high resolution experiments - will reveal insights that will allow us to try to democratize and make drug discovery simpler and cheaper" Swamy Vijayan, Founder & CEO Zafrens on Bio_Unlock Episode #002: The Future of Drug Discovery. Watch the full conversation here: https://lnkd.in/dXmDRds6 (or wherever you get your podcasts)

  • View organization page for Zafrens, graphic

    2,185 followers

    Our CEO, Kandaswamy (Swamy) Vijayan recently joined a podcast Bio_Unlock hosted by BlueYard Capital, alongside Elliot Hershberg, author of the popular newsletter "Century of Biology". Swamy discussed his interdisciplinary approach that merges biology, chemistry, and engineering to understand and manipulate cell states. By miniaturizing experiments and screening at ultra-high throughput, Zafrens is challenging traditional drug discovery methods, enabling the study of thousands of cells simultaneously. Elliot shared insights into the evolution of biotech towards "tech bio," emphasizing the importance of engineering disciplines in revolutionizing biological research. They discussed the transformative potential of AI and machine learning in analyzing vast datasets and guiding experimental design.  Thanks to Elliot, Anastasia, and BlueYard Capital for the insightful discussion! 🎙️ #Immunotherapy #Innovation #startup Direct link here: https://lnkd.in/dXmDRds6

    View organization page for BlueYard Capital, graphic

    4,529 followers

    "We think [this approach] to drug discovery and analysis where we miniaturize everything - we do high throughput experiments, but also high resolution experiments - will reveal insights that will allow us to try to democratize and make drug discovery simpler and cheaper" Swamy Vijayan, Founder & CEO Zafrens on Bio_Unlock Episode #002: The Future of Drug Discovery. Watch the full conversation here: https://lnkd.in/dXmDRds6 (or wherever you get your podcasts)

  • View organization page for Zafrens, graphic

    2,185 followers

    We are excited to announce that our CEO Kandaswamy (Swamy) Vijayan will be joining a panel discussion at the Precision Medicine World Conference #PMWC24 next week!  Register for the conference here: https://lnkd.in/gM_Xxdi7 Follow our page for future updates at Zafrens Are you interested in learning more about Zafrens or our recently launched Ultra High-Throughput Functional Genomics "Z-Screen" Platform? Leave a message at hello@zafrens.com PMWC - Precision Medicine World ConferenceTal Behar, #PMWC24

    • No alternative text description for this image

Similar pages

Funding

Zafrens 3 total rounds

Last Round

Series A

US$ 23.0M

See more info on crunchbase